Pathogen Reduction Technologies and Their Impact on Metabolic and Functional Properties of Treated Platelet Concentrates: A Systematic Review

被引:5
作者
Tsalas, Stavros [1 ]
Petrou, Eleni [1 ]
Tsantes, Andreas G. [1 ]
Sokou, Rozeta [2 ]
Loukopoulou, Electra [1 ]
Houhoula, Dimitra [1 ]
Mantzios, Petros G. [1 ]
Kriebardis, Anastasios G. [3 ]
Tsantes, Argirios E. [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Attiko Hosp, Sch Med, Lab Haematol & Blood Bank Unit, Athens, Greece
[2] Agios Panteleimon Gen Hosp Nikea, Neonatal Intens Care Unit, Piraeus, Greece
[3] Univ West Attica, Sch Hlth & Caring Sci, Dept Biomed Sci, Lab Reliabil & Qual Control,Lab Hematol, Athens, Greece
关键词
pathogen reduction technologies; pathogen inactivated platelets; platelet storage lesion; platelet function; IN-VITRO EVALUATION; ULTRAVIOLET-LIGHT TREATMENT; BUFFY COAT PLATELETS; ADDITIVE SOLUTION; HEMOSTATIC FUNCTION; THROMBUS FORMATION; AMOTOSALEN-HCL; PHOTOCHEMICAL INACTIVATION; APHERESIS PLATELETS; PROTEOMIC ANALYSIS;
D O I
10.1055/s-0042-1757897
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pathogen reduction technologies (PRTs) such as Mirasol and Intercept were developed to eliminate transfusion-transmitted infections. The impact of PRTs on platelet function during the storage period, their effect on platelet storage lesions, and the optimal storage duration following PRTs have not been clearly defined. The aim of this study was to systematically review the existing literature and investigate the impact of PRTs on functional alterations of PRT-treated platelets during the storage period. The authors identified 68 studies suitable to be included in this review. Despite the high heterogeneity in the literature, the results of the published studies indicate that PRTs may increase platelet metabolic activity, accelerate cell apoptosis, and enhance platelet activation, which can subsequently lead to a late exhaustion of activation potential and reduced aggregation response. However, these effects have a minor impact on platelet function during the early storage period and become more prominent beyond the fifth day of the storage period. Large in vivo trials are required to evaluate the effectiveness of PRT-treated platelets during the storage period and investigate whether their storage can be safely extended to more than 5 days, and up to the traditional 7-day storage period.
引用
收藏
页码:523 / 541
页数:19
相关论文
共 76 条
[41]   Upregulation of GP IIb/IlIa receptors during platelet activation: Influence on efficacy of receptor blockade [J].
Matzdorff, A ;
Voss, R .
THROMBOSIS RESEARCH, 2006, 117 (03) :307-314
[42]   Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates [J].
Middelburg, Rutger A. ;
Roest, Mark ;
Ham, Jannemieke ;
Coccoris, Miriam ;
Zwaginga, Jaap Jan ;
van der Meer, Pieter F. .
TRANSFUSION, 2013, 53 (08) :1780-1787
[43]   In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days [J].
Moog, R ;
Fröhlich, A ;
Mayaudon, V ;
Lin, L .
JOURNAL OF CLINICAL APHERESIS, 2004, 19 (04) :185-191
[44]   Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function [J].
Osman, Abdimajid ;
Hitzler, Walter E. ;
Meyer, Claudius U. ;
Landry, Patricia ;
Corduan, Aurelie ;
Laffont, Benoit ;
Boilard, Eric ;
Hellstern, Peter ;
Vamvakas, Eleftherios C. ;
Provost, Patrick .
PLATELETS, 2015, 26 (02) :154-163
[45]   Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology [J].
Ostrowski, Sisse R. ;
Bochsen, Louise ;
Windelov, Nis A. ;
Salado-Jimena, Jose A. ;
Reynaerts, Inge ;
Goodrich, Raymond P. ;
Johansson, Par I. .
TRANSFUSION, 2011, 51 (02) :344-356
[46]   In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology [J].
Ostrowski, Sisse R. ;
Bochsen, Louise ;
Salado-Jimena, Jose A. ;
Ullum, Henrik ;
Reynaerts, Inge ;
Goodrich, Raymond P. ;
Johansson, Par I. .
TRANSFUSION, 2010, 50 (10) :2210-2219
[47]   Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates [J].
Perez-Pujol, S ;
Tonda, R ;
Lozano, M ;
Fuste, B ;
Lopez-Vilchez, I ;
Galan, AM ;
Li, J ;
Goodrich, R ;
Escolar, G .
TRANSFUSION, 2005, 45 (06) :911-919
[48]   Haemostatic profile of riboflavin-treated apheresis platelet concentrates [J].
Petrou, Eleni ;
Nikolopoulos, Georgios K. ;
Kriebardis, Anastasios G. ;
Pantavou, Katerina ;
Loukopoulou, Electra ;
Tsantes, Andreas G. ;
Georgatzakou, Hara T. ;
Maratou, Eirini ;
Rapti, Evdoxia ;
Mellou, Sofia ;
Kokoris, Styliani ;
Gialeraki, Argyri ;
Tsantes, Argirios E. .
BLOOD TRANSFUSION, 2022, 20 (03) :223-234
[49]   Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction [J].
Picker, S. M. ;
Oustianskaia, L. ;
Schneider, V. ;
Gathof, B. S. .
VOX SANGUINIS, 2009, 97 (01) :26-33
[50]   Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation [J].
Picker, SM ;
Speer, R ;
Gathof, BS .
TRANSFUSION, 2004, 44 (03) :320-329